Biotech Dealmaking: Novartis will pay $125M up front for Sironax’s blood-brain barrier delivery platform, underscoring how Boston-area drugmakers are turning delivery tech into big pharma leverage. Clinical Progress: Skyhawk Therapeutics reported final results for its once-daily Huntington’s “RNA splicing” pill, with mutant huntingtin reductions of 60%+ and functional gains versus untreated patients, pushing the program into larger trials. Medtech Portfolio Shifts: J&J is selling Laminar left atrial appendage closure assets to a new owner, after a suspended study raised concerns about post-implant leaks—another reminder that device risk can reshape corporate strategy fast. AI & Health Tech: Spectral AI highlighted its DeepView burn wound system at a major burn conference, while Avalyn added FDA/regulatory heavyweight Robert J. Meyer to its board as it advances inhaled respiratory candidates. Local Tech & Privacy: Boston’s Flock camera fallout continues, with Barnstable pointing to ALPR value after canceling Flock—while other communities move to restrict or remove the tech. Policy & Regulation: Massachusetts AG Andrea Joy Campbell says Meta must change default protections for young users, including age limits and daily time controls. Economy & Rates: The Fed raised rates again, with projections pointing to at least one more hike this year—pressuring credit while rattling markets. STEM & Education: WPI won NSF funding for student scholarships and STEM programs, and Boston tapped Emily Knight to lead economic development, signaling a continued push for “tough tech” startups.